Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conservative Treatments for Supraspinatus Tendon Injury
NCT06631976Recruiting
- Sponsor
- Medical University of Lodz
- Start
- Jun 2024
- Primary completion
- May 2026
- Modality
- Adipose-derived MSCs, Orthosteric Ligands, Bone Marrow MSCs
- Countries
- 1
01
Overview
Randomised trial of methylprednisolone, platelet-rich plasma and lidocaine in supraspinatus tendon tear and sleep disorder (4 arms), sponsored by Medical University of Lodz. Primary endpoints: Constant-Murley Score at 6 months, Numeric Pain Rating Scale at 6 months and 4 more. Started Jun 2024; status: recruiting.
02
Drugs
methylprednisoloneplatelet-rich plasmalidocaine
03
Conditions
supraspinatus tendon tearsleep disorder
Beyond the preview
Go deeper on NCT06631976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631976.